Provided by Tiger Fintech (Singapore) Pte. Ltd.

AINOS Inc.

0.5500
+0.0000
Post-market: 0.5432-0.0068-1.24%19:34 EDT
Volume:110.89K
Turnover:61.11K
Market Cap:8.49M
PE:-0.35
High:0.5699
Open:0.5500
Low:0.5430
Close:0.5500
Loading ...

Company Profile

Company Name:
AINOS Inc.
Exchange:
NASDAQ
Establishment Date:
1984
Employees:
44
Office Location:
8880 Rio San Diego Drive,Suite 800,San Diego,California,United States
Zip Code:
92108
Fax:
- -
Introduction:
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

Directors

Name
Position
Chun Hsien Tsai
Chairman of the Board, President and Chief Executive Officer
Chun Jung Tsai
Director
Chung Yi Tsai
Director
Pao Sheng Wei
Director
Ting Chuan Lee
Director
Wen Han Chang
Director
Yao Chung Chiang
Director

Shareholders

Name
Position
Chun Hsien Tsai
Chairman of the Board, President and Chief Executive Officer
Hui Lan Wu
Chief Financial Officer
Lawrence K. Lin
Executive Vice President of Operations